
    
      Descriptive multicenter study including patients with refractory cancer pain (unmanageable
      drug sides effects or intractable pain) who will receive intrathecal analgesia Patient
      discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia
      at 15, 30, 60 and 90 days.

      Moreover, the impact on patient close relatives and on return home will be assessed.
    
  